The move comes following an inquiry in Saurya Pratap’s case who was treated for dengue at a city private hospital.
“We are seeking technical opinion before finalising the notice. The company will get 15-days time to respond,” said Sandeep Gahlain, drug control officer, Gurugram.
He added that every company has to get the MRP approved by the national pharmaceutical pricing authority (NPPA) when they launch a new drug. However, this company that manufactured dexamethasone injection, which was used in Saurya’s treatment, had an MRP which was higher than the prescribed price.